US Patent No: 7,749,542

Number of patents in Portfolio can not be more than 2000

Opioid agonist/antagonist combinations

ALSO PUBLISHED AS: 20080292694

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PURDUE PHARMA L.P.STAMFORD, CT277

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Colucci, Robert D Newtown, CT 23 707
Kaiko, Robert F Weston, CT 46 1188

Cited Art Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (39)
4,828,836 Controlled release pharmaceutical composition 160 1987
4,834,985 Controlled release pharmaceutical composition 184 1987
4,990,341 Controlled release hydromorphone composition 109 1989
5,266,331 Controlled release oxycodone compositions 128 1991
5,273,760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 168 1991
5,286,493 Stabilized controlled release formulations having acrylic polymer coating 165 1992
5,549,912 Controlled release oxycodone compositions 120 1993
5,472,712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 148 1993
5,478,577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 133 1993
5,411,745 Powder-layered morphine sulfate formulations 87 1994
5,965,161 Extruded multi-particulates 99 1994
5,639,476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 331 1995
5,508,042 Controlled release oxycodone compositions 125 1995
5,968,551 Orally administrable opioid formulations having extended duration of effect 138 1995
5,958,459 Opioid formulations having extended controlled released 83 1995
5,656,295 Controlled release oxycodone compositions 107 1996
5,681,585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 81 1996
5,672,360 Method of treating pain by administering 24 hour oral opioid formulations 133 1996
6,143,322 Method of treating humans with opioid formulations having extended controlled release 94 1997
5,958,452 Extruded orally administrable opioid formulations 123 1997
5,968,547 Method of providing sustained analgesia with buprenorphine 75 1997
6,077,533 Powder-layered oral dosage forms 54 1998
6,228,863 Method of preventing abuse of opioid dosage forms 115 1998
6,277,384 Opioid agonist/antagonist combinations 84 1998
6,103,261 Opioid formulations having extended controlled release 88 1999
6,335,033 Melt-extrusion multiparticulates 64 1999
6,261,599 Melt-extruded orally administrable opioid formulations 103 1999
6,294,195 Orally administrable opioid formulations having extended duration of effect 91 1999
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations 109 2000
6,696,088 Tamper-resistant oral opioid agonist formulations 88 2001
6,475,494 Opioid agonist/antagonist combinations 63 2001
2003/0069,263 Pharmaceutical combinations of oxycodone and naloxone 42 2002
2003/0073,714 Opioid agonist formulations with releasable and sequestered antagonist 40 2002
6,696,066 Opioid agonist/antagonist combinations 79 2002
2003/0229,111 Naltrexone hydrochloride compositions 14 2003
2004/0186,121 Tamper-resistant oral opioid agonist formulations 34 2003
7,172,767 Opioid agonist / antagonist combinations 42 2003
2006/0182,801 Sequestered antagonist formulations 33 2006
7,419,686 Opioid agonist/antagonist combinations 22 2006
 
EURO-CELTIQUE S.A. (35)
4,366,310 Controlled release compositions 45 1980
4,940,587 Oral pharmaceutical composition through mucosa 97 1986
4,844,907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 118 1986
4,834,965 Controlled release pharmaceutical composition 76 1987
4,867,985 Spheroids 79 1988
5,071,646 Pharmaceutical ion exchange resin composition 100 1989
5,091,189 Controlled release dosage forms having a defined water content 39 1991
5,215,758 Controlled release matrix suppository for pharmaceuticals 75 1991
5,324,351 Aqueous dispersions of zein and preparation thereof 85 1992
5,356,467 Controlled release coatings derived from aqueous dispersions of zein 128 1993
5,500,227 Immediate release tablet cores of insoluble drugs having sustained-release coating 125 1993
5,622,722 Spheroid formulation 38 1994
5,508,043 Controlled release matrix for pharmaceuticals 46 1995
5,670,172 Pharmaceutical spheroid formulation 62 1995
6,024,982 Immediate release tablet cores of insoluble drugs having sustained-release coating 85 1995
5,811,126 Controlled release matrix for pharmaceuticals 67 1995
5,763,452 Pharmaceutical compositions and usages 37 1996
5,849,240 Method of preparing sustained release pharmaceutical compositions 93 1996
5,891,471 Pharmaceutical multiparticulates 84 1996
5,601,845 Pharmaceutical spheroid formulation 75 1996
5,843,480 Controlled release diamorphine formulation 65 1996
5,879,705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 86 1997
5,908,848 Synergistic composition of codine and ibuprofen to treat arthritis 39 1997
5,942,241 Formulations and methods for providing prolonged local anesthesia 109 1997
6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 60 1997
5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions 93 1997
6,077,532 Pharmaceutical ion exchange resin composition 44 1998
6,306,438 Stabilized sustained release tramadol formulations 59 1998
6,399,096 Pharmaceutical formulation 52 1998
6,143,328 Sustained release compositions and a method of preparing pharmaceutical compositions 45 1999
6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions 67 1999
6,210,714 Immediate release tablet cores of acetaminophen having sustained-release coating 60 2000
6,387,404 Immediate release tablet cores of insoluble drugs having sustained-release coating 61 2001
6,716,449 Controlled-release compositions containing opioid agonist and antagonist 64 2001
6,627,635 Method of preventing abuse of opioid dosage forms 75 2001
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (12)
5,472,943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 80 1993
5,585,348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 68 1993
5,512,578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 88 1994
5,624,932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 44 1995
5,580,876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 71 1995
5,767,125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 73 1996
6,096,756 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 71 1998
6,194,382 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 44 1999
2001/0006,967 METHOD OF SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING ADVERSE SIDE EFFECTS CAUSED BY TRAMADOL AND OTHER BIMODALLY-ACTING OPIOID AGONISTS 17 1999
6,362,194 Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 33 2000
6,395,705 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 41 2001
6,765,010 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects 34 2002
 
MERCK FROSST CANADA LTD. (10)
5,409,944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 68 1993
5,604,260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 80 1993
5,436,265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 83 1993
5,521,213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 90 1994
5,552,422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 97 1995
5,536,752 Phenyl heterocycles as COX-2 inhibitors 76 1995
5,550,142 Phenyl heterocycles as cox-2 inhibitors 82 1995
5,510,368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 86 1995
5,604,253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 69 1995
5,639,780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 67 1995
 
ALZA CORPORATION (6)
4,200,098 Osmotic system with distribution zone for dispensing beneficial agent 312 1978
4,285,987 Process for manufacturing device with dispersion zone 281 1979
4,573,995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 131 1984
5,236,714 Abusable substance dosage form having reduced abuse potential 90 1988
5,460,826 Morphine therapy 86 1994
5,866,164 Composition and dosage form comprising opioid antagonist 110 1997
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4,401,672 Non-addictive narcotic antitussive preparation 56 1981
4,730,048 Gut-selective opiates 76 1985
5,352,680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 97 1992
5,457,208 Kappa opioid receptor antagonists 69 1993
5,578,725 Delta opioid receptor antagonists 51 1995
5,780,479 Use of opioid antagonists to treat impulse-control disorders 47 1997
 
UNIVERSITY OF CHICAGO, THE (4)
4,719,215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 79 1986
4,861,781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 74 1987
5,102,887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 75 1990
5,972,954 Use of methylnaltrexone and related compounds 87 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5,352,683 Method for the treatment of chronic pain 76 1993
5,321,012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 116 1993
5,502,058 Method for the treatment of pain 98 1994
5,556,838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 109 1994
 
CONTRAL CLINICS OY (3)
4,882,335 Method for treating alcohol-drinking response 71 1988
5,096,715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 54 1989
5,086,058 Method for treating alcoholism with nalmefene 69 1990
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5,591,452 Controlled release formulation 77 1994
6,326,027 Controlled release formulation 66 1995
6,254,887 Controlled release tramadol 62 1996
 
The Rockefeller University (3)
4,987,136 Method for controlling gastrointestinal dysmotility 106 1986
4,769,372 Method of treating patients suffering from chronic pain or chronic cough 80 1986
4,785,000 Method of treating patients suffering from chronic pain or chronic cough 58 1987
 
BASF AKTIENGESELLSCHAFT (2)
4,806,558 Diarylacetylenes and their use in treating acne 49 1985
4,957,681 Preparation of pharmaceutical mixtures 87 1989
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4,451,470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 58 1982
5,593,994 Prostaglandin synthase inhibitors 63 1994
 
Eli Lilly and Company (2)
4,293,539 Controlled release formulations and method of treatment 96 1979
5,998,434 Composition for treating pain 42 1998
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4,844,909 Controlled release hydromorphone composition 103 1987
4,844,910 Spheroids 48 1987
 
NOVA PHARMACEUTICAL CORPORATION (2)
4,760,069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 60 1985
4,889,860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 64 1987
 
OMEROS CORPORATION (2)
5,858,017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 101 1996
5,860,950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 87 1996
 
PURDUE PHARMA COMPANY, THE (2)
4,861,598 Controlled release bases for pharmaceuticals 131 1986
4,970,075 Controlled release bases for pharmaceuticals 106 1989
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4,582,835 Analgesic compositions 98 1984
4,661,492 Analgesic compositions 68 1985
 
Schaap; Robert J. (2)
5,316,759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 63 1992
5,574,052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 113 1994
 
ADIR ET COMPAGNIE (1)
5,130,311 Oxazolopyridine compounds, compositions and use 46 1991
 
Aminotek Sciences, Inc. (1)
5,256,669 Methods and compositions for treating acute or chronic pain and drug addiction 55 1992
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4,873,076 Method of safely providing anesthesia or conscious sedation 58 1989
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4,457,933 Prevention of analgesic abuse 95 1981
 
COLMAN PRODUCTS LIMITED (1)
4,935,428 Treating opiate dependence 68 1988
 
DUPONT MERCK PHARMACEUTICAL COMPANY, THE (1)
4,722,928 N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes 22 1985
 
DUPONT PHARMACEUTICALS COMPANY (1)
4,237,140 Analgesic mixture of nalbuphine and acetaminophen 53 1979
 
DYNAGEN, INC. (1)
5,486,362 Controlled, sustained release delivery system for treating drug dependency 93 1993
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5,869,097 Method of therapy comprising an osmotic caplet 57 1992
 
G. D. Searle & Co. (1)
5,616,601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 114 1995
 
GENERAL ELECTRIC COMPANY (1)
5,226,331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 40 1991
 
ICN HUNGARY RT. (1)
5,317,022 Pharmaceutical composition and use 54 1992
 
LIFESHIELD SCIENCES LLC (1)
2004/0158,312 Braided endoluminal device having tapered filaments 5 2003
 
McGinnis; Carolyn (1)
4,608,376 Opiate agonists and antagonists 47 1982
 
MERCK FROSST COMPANY (1)
5,474,995 Phenyl heterocycles as cox-2 inhibitors 149 1994
 
MERCK SHARP & DOHME LTD. (1)
5,880,132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 54 1997
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,225,440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 54 1991
 
OREGON, UNIVERSITY OF (1)
5,514,680 Glycine receptor antagonists and the use thereof 63 1993
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (1)
5,336,691 Composition comprising a tramadol material and acetaminophen and its use 66 1992
 
PEPTECH LIMITED (1)
5,534,492 Muramyl peptide for the treatment of toxicity 44 1995
 
PUREUE PHARMA L.P. (1)
4,834,984 Controlled release dihydrocodeine composition 98 1987
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4,806,341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 107 1986
 
SCULLY SCOTT MURPHY & PRESSER, PC (1)
5,426,112 Growth regulation and related applications of opioid antagonists 81 1993
 
SIMON, DAVID L. (1)
6,103,258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 42 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4,803,208 Opiate agonists and antagonists 51 1985
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4,806,543 Method and compositions for reducing neurotoxic injury 73 1986
 
The Lynx Project Limited (1)
6,310,072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 44 1997
 
THE MCLEAN HOSPITAL CORPORATION (1)
5,075,341 Treatment for cocaine abuse 114 1989
 
The United States of America as represented by the Secretary of the Army (1)
5,834,477 Opiate analgesic formulation with improved safety 38 1994
 
United Biomedical, Inc. (1)
5,633,259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 46 1995
 
Warner-Lambert Company (1)
5,149,538 Misuse-resistive transdermal opioid dosage form 137 1991
 
YOUNG, JACQUELINE, MS. (1)
5,356,900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 51 1993
 
Other [Check patent profile for assignment information] (7)
4,464,378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 141 1981
4,443,428 Extended action controlled release compositions 80 1982
5,376,662 Method of attenuating nerve injury induced pain 49 1993
2004/0092,542 Tamper-resistant oral opioid agonist formulations 28 2003
2005/0095,291 Tamper-resistant oral opioid agonist formulations 39 2003
2005/0181,046 Tamper-resistant oral opioid agonist formulations 29 2003
2006/0039,970 Tamper-resistant oral opioid agonist formulations 20 2003

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (6)
8,518,925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 0 2005
8,105,631 Opioid agonist/antagonist combinations 6 2010
8,673,355 Opioid agonist/antagonist combinations 0 2011
8,846,090 Matrix for sustained, invariant and independent release of active compounds 0 2012
8,822,487 Opioid agonist/opioid antagonist/acetaminophen combinations 0 2012
8,846,091 Matrix for sustained, invariant and independent release of active compounds 0 2013
 
EGALET LTD. (1)
8,808,745 Morphine polymer release system 0 2013

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 6, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 6, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00